Examining the Details of the Recent Updates to MS-DRGs

As we near the end of what some consider the most unprecedented year in coding, there are more updates to review and decipher in preparation for 2021.  

As the science around the COVID-19 pandemic continues to evolve, there remain many unknowns of post-COVID-related conditions. There is an ongoing and urgent need to capture more information about the disease by the global healthcare community.

The Centers for Disease Control and Prevention (CDC), under the National Emergencies Act Section 201 and 301, announced further additions to ICD-10-CM classification related to COVID-19. Additionally, the Centers for Medicare & Medicaid Services (CMS) has posted new guidelines for ICD-10 CM/PCS coding and an updated MS-DRGs, Version 38.1 ─ all effective Jan. 1, 2021. Updates include new ICD-10-CM and PCS codes for COVID-19.

ICD-10 MS-DRGs, Version 38.1 

The ICD-10 MS-DRG grouper software package to accommodate these new codes, Version 38.1, is effective for discharges on or after Jan. 1, 2021.

The six new diagnosis codes proposed are:

  • 82, Pneumonia due to coronavirus disease 2019
  • 81, Multisystem inflammatory syndrome
  • 89, Other specified systemic involvement of connective tissue
  • 52, Encounter for screening for COVID-19
  • 822, Contact with and (suspected) exposure to COVID-19
  • 16, Personal history of COVID-19

The new diagnosis codes were proposed and discussed in detail at the September 2020 ICD-10 Coordination and Maintenance Committee (C&M) meeting. The CDC announcement, along with the new codes and their MS-DRG assignment, is available as a one-page PDF on the CMS website, and the Index and Tabular Addenda for the new codes will be posted on the CDC’s ICD-10 CM page.

COVID-19 Therapeutics and Vaccines

In addition to new ICD-10-PCS codes for the administration of remdesivir and transfusion of convalescent plasma (implemented earlier this year and effective Aug. 1, 2020), the 21 new PCS codes (effective Jan. 1, 2021) include codes to capture the use of additional COVID-19 therapeutics, as well as administration of COVID-19 vaccines.

All of these new PCS codes are classified in table XW0 of the ICD-10-PCS. The codes specify the substance name or type and administration route – whether by subcutaneous/intramuscular injection, IV infusion, or oral administration.

Monoclonal Antibody (10 codes)

Four specific substances classified as monoclonal antibodies – Bamlanivimab, Etesevimab, Leronlimab, and REGN-COV2 – have new PCS codes to track their use in treating COVID-19. Leronlimab is administered by subcutaneous injection, and the other three substances are administered via IV infusion.

  • XW013K6, Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW043E6, Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033E6, Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033F6, Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043F6, Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033G6, Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043G6, Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Three non-specific monoclonal antibody codes were added to allow tracking of other monoclonal antibody drugs approved for the treatment of COVID-19 in the coming months:

  • XW033H6, Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043H6, Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW013H6, Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Other Drug Class (5 codes)

Two specific substances – the drug baracitinib (trade name Olumiant®) and an immunomodulator drug known as CD24Fc – also have new codes for tracking their use as COVID-19 therapies. Baracitinib recently received Food and Drug Administration (FDA) emergency use authorization (EUA) as a treatment for COVID-19, in combination with remdesivir. Baracitinib can be administered orally or via gastrostomy/jejunostomy tube. The immunomodulator substance designated CD24Fc is administered via IV infusion.

  • XW0DXM6, Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
  • XW0G7M6, Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
  • XW0H7M6, Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
  • XW043L6, Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033L6, Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Vaccine (6 codes)

Six new PCS codes were added for tracking COVID-19 vaccination while a patient is in the hospital. Likely, the vast majority of vaccines will not be administered to patients while they are in the hospital; nevertheless, these PCS codes will allow for the applicable data to be captured on an inpatient record.

The new PCS codes specify whether the vaccine was a subcutaneous or intramuscular injection, and whether the injection was the first dose or the second, for vaccines that require two injections to complete the therapy. The codes that do not specify dose are to be used for single-dose vaccinations, or when information regarding the dose is not available in the medical record.

  • XW013S6, Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013T6, Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013U6, Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW023S6, Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023T6, Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023U6, Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

For MS-DRGs, the new PCS codes are designated Non-OR and will not affect DRG assignment. However, CMS noted in their official announcement, “for hospitalized patients; Medicare pays for the COVID-19 vaccines and their administration separately from the Diagnosis-Related Group rate. As such, Medicare expects that the appropriate CPT codes will be used when a Medicare beneficiary is administered a vaccine while a hospital inpatient.”

 

The CMS announcement, which contains the list of 21 PCS codes, can be accessed on the CMS website here: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software

The Index and Tabular Addenda for the new codes can be found on the CDC’s ICD-10-CM page: https://www.cdc.gov/nchs/icd/icd10cm.htm

Programming Note: Listen to Susan Gatehouse report this story live today during Talk Ten Tuesdays, 10 a.m. EST.

Facebook
Twitter
LinkedIn

Susan Gatehouse, RHIT, CCS,CPC, AHIMA-Approved ICD-10-CM/PCS Trainer

Susan Gatehouse is the founder and chief executive officer of Axea Solutions. An industry expert in revenue cycle management, Gatehouse established Axea Solutions in 1998, and currently partners with healthcare organizations across the nation, to craft solutions for unique challenges in the dynamic world of healthcare reimbursement and data management.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24